Correction to: Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer's disease.

Abstract:

:Following publication of the original article [1], the authors reported that Fig. 6 contains a mistake. The Fig. 6F is a duplicate of Fig. 6E of Braak 5.

journal_name

Alzheimers Res Ther

authors

Hishimoto A,Pletnikova O,Lang DL,Troncoso JC,Egan JM,Liu QR

doi

10.1186/s13195-019-0493-0

subject

Has Abstract

pub_date

2019-05-07 00:00:00

pages

39

issue

1

issn

1758-9193

pii

10.1186/s13195-019-0493-0

journal_volume

11

pub_type

已发布勘误
  • Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.

    abstract:INTRODUCTION:Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0143-0

    authors: Coutinho AM,Porto FH,Duran FL,Prando S,Ono CR,Feitosa EA,Spíndola L,de Oliveira MO,do Vale PH,Gomes HR,Nitrini R,Brucki SM,Buchpiguel CA

    更新日期:2015-09-15 00:00:00

  • Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease.

    abstract:INTRODUCTION:There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease (AD) assessed by repeated measures on serial tests of cognition and function. METHODS:Six hundre...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt7

    authors: Rountree SD,Chan W,Pavlik VN,Darby EJ,Siddiqui S,Doody RS

    更新日期:2009-10-21 00:00:00

  • PERK: a novel therapeutic target for neurodegenerative diseases?

    abstract::Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (pro...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt260

    authors: Ma T,Klann E

    更新日期:2014-05-29 00:00:00

  • A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

    abstract:BACKGROUND:In Alzheimer's disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeutic strategy is to decrease the production of potentially toxic beta-amyloid species by the use of i...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章

    doi:10.1186/s13195-016-0178-x

    authors: Hölttä M,Dean RA,Siemers E,Mawuenyega KG,Sigurdson W,May PC,Holtzman DM,Portelius E,Zetterberg H,Bateman RJ,Blennow K,Gobom J

    更新日期:2016-03-07 00:00:00

  • ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.

    abstract:BACKGROUND:Blood-based biomarkers for Alzheimer's disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphorylated tau in cerebrospinal fluid (CSF); however, they are not attractive for large-scale screening. Bl...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00750-y

    authors: Oliveira Monteiro MPA,Salheb Oliveira DSM,Manzine PR,Crispim Nascimento CM,Dos Santos Orlandi AA,de Oliveira Gomes GA,Dos Santos Orlandi F,Zazzetta MS,Pott-Junior H,Cominetti MR

    更新日期:2021-01-08 00:00:00

  • Older patients are still under-represented in clinical trials of Alzheimer's disease.

    abstract:BACKGROUND:The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research are systematically younger than those in the general population. We examined the age gap between pa...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-016-0201-2

    authors: Banzi R,Camaioni P,Tettamanti M,Bertele' V,Lucca U

    更新日期:2016-08-12 00:00:00

  • Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?

    abstract::Parkinson's disease, the most common movement disorder, results in an insidious reduction for patients in quality of life and ability to function. A hallmark of Parkinson's disease is the brain accumulation of neuronal cytoplasmic inclusions comprised of the protein α-synuclein. The presence of α-synuclein brain aggre...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt151

    authors: Sacino AN,Giasson BI

    更新日期:2012-12-17 00:00:00

  • Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.

    abstract:INTRODUCTION:Peripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may differentiate patients clinically defined with probable AD from noncognitive impaired controls. METHOD...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt186

    authors: Donovan LE,Dammer EB,Duong DM,Hanfelt JJ,Levey AI,Seyfried NT,Lah JJ

    更新日期:2013-06-13 00:00:00

  • Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease.

    abstract:INTRODUCTION:There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testostero...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0107-4

    authors: Hall JR,Wiechmann AR,Cunningham RL,Johnson LA,Edwards M,Barber RC,Singh M,Winter S,O'Bryant SE,Texas Alzheimer’s Research and Care Consortium.

    更新日期:2015-05-01 00:00:00

  • Systematic reviews on behavioural and psychological symptoms in the older or demented population.

    abstract:INTRODUCTION:Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demented and demented population. METHODS:We have undertaken a systematic review of reviews to give a ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt131

    authors: van der Linde RM,Stephan BC,Savva GM,Dening T,Brayne C

    更新日期:2012-07-11 00:00:00

  • Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.

    abstract:BACKGROUND:In patients with amyloid-positive mild cognitive impairment (MCI), neurodegenerative biomarkers such as medial temporal lobe atrophy (MTA) are useful to predict disease progression to dementia. Although posterior atrophy (PA) is a well-known neurodegenerative biomarker of Alzheimer's disease, little is known...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0326-y

    authors: Pyun JM,Park YH,Kim HR,Suh J,Kang MJ,Kim BJ,Youn YC,Jang JW,Kim S,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2017-12-16 00:00:00

  • Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?

    abstract::The strongest known risk factors for late-onset Alzheimer disease (LOAD) remain a positive family history and the APOE epsilon4 allele. van Exel and colleagues used these known risk factors to identify high- and low-risk samples of middle-aged persons in whom they compared levels of inflammatory and vascular risk fact...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/alzrt29

    authors: Tan ZS,Seshadri S

    更新日期:2010-04-12 00:00:00

  • Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery.

    abstract::The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alzheimer's Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical devel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt159

    authors: Lane RF,Dacks PA,Shineman DW,Fillit HM

    更新日期:2013-02-04 00:00:00

  • Study partners: essential collaborators in discovering treatments for Alzheimer's disease.

    abstract:BACKGROUND:Global leaders have set an ambitious goal of developing interventions to effectively treat or prevent Alzheimer's disease by 2025. CASE PRESENTATION:Achieving this goal will require clinical trials to test promising interventions, yet Alzheimer's researchers are confronting a clinical trial recruitment cris...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/s13195-018-0425-4

    authors: Largent EA,Karlawish J,Grill JD

    更新日期:2018-09-27 00:00:00

  • Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.

    abstract:BACKGROUND:Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer's disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance remains a challenge. In the present study, we used transferrin receptor (TfR)-mediated transcytosis to f...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0377-8

    authors: Syvänen S,Hultqvist G,Gustavsson T,Gumucio A,Laudon H,Söderberg L,Ingelsson M,Lannfelt L,Sehlin D

    更新日期:2018-05-24 00:00:00

  • Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study.

    abstract:BACKGROUND:We developed multifactorial models for predicting incident dementia and brain pathology in the oldest old using the Vantaa 85+ cohort. METHODS:We included participants without dementia at baseline and at least 2 years of follow-up (N = 245) for dementia prediction or with autopsy data (N = 163) for patholog...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0450-3

    authors: Hall A,Pekkala T,Polvikoski T,van Gils M,Kivipelto M,Lötjönen J,Mattila J,Kero M,Myllykangas L,Mäkelä M,Oinas M,Paetau A,Soininen H,Tanskanen M,Solomon A

    更新日期:2019-01-22 00:00:00

  • Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

    abstract:BACKGROUND:The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Ce...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0478-z

    authors: Salvadó G,Molinuevo JL,Brugulat-Serrat A,Falcon C,Grau-Rivera O,Suárez-Calvet M,Pavia J,Niñerola-Baizán A,Perissinotti A,Lomeña F,Minguillon C,Fauria K,Zetterberg H,Blennow K,Gispert JD,Alzheimer’s Disease Neuroimaging Init

    更新日期:2019-03-21 00:00:00

  • Analysis of brain region-specific co-expression networks reveals clustering of established and novel genes associated with Alzheimer disease.

    abstract:BACKGROUND:Identifying and understanding the functional role of genetic risk factors for Alzheimer disease (AD) has been complicated by the variability of genetic influences across brain regions and confounding with age-related neurodegeneration. METHODS:A gene co-expression network was constructed using data obtained...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00674-7

    authors: Lancour D,Dupuis J,Mayeux R,Haines JL,Pericak-Vance MA,Schellenberg GC,Crovella M,Farrer LA,Kasif S

    更新日期:2020-09-02 00:00:00

  • Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

    abstract:BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1186/s13195-016-0181-2

    authors: Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

    更新日期:2016-04-06 00:00:00

  • Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

    abstract:BACKGROUND:Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice. However, this is controversial given the current lack of understanding of the predictive value of a P...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0398-3

    authors: de Wilde A,van Buchem MM,Otten RHJ,Bouwman F,Stephens A,Barkhof F,Scheltens P,van der Flier WM

    更新日期:2018-07-28 00:00:00

  • Retinal microvasculature dysfunction is associated with Alzheimer's disease and mild cognitive impairment.

    abstract:BACKGROUND:The retina and brain share many neuronal and vasculature characteristics. We investigated the retinal microvasculature in Alzheimer's disease (AD) and mild cognitive impairment (MCI) using optical coherence tomography angiography (OCTA). METHODS:In this cross-sectional study, 24 AD participants, 37 MCI part...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00724-0

    authors: Chua J,Hu Q,Ke M,Tan B,Hong J,Yao X,Hilal S,Venketasubramanian N,Garhöfer G,Cheung CY,Wong TY,Chen CL,Schmetterer L

    更新日期:2020-12-04 00:00:00

  • Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

    abstract::Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson's disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep, and motor features...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-020-00703-5

    authors: Goldman JG,Forsberg LK,Boeve BF,Armstrong MJ,Irwin DJ,Ferman TJ,Galasko D,Galvin JE,Kaufer D,Leverenz J,Lippa CF,Marder K,Abler V,Biglan K,Irizarry M,Keller B,Munsie L,Nakagawa M,Taylor A,Graham T

    更新日期:2020-10-29 00:00:00

  • Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice.

    abstract:BACKGROUND:Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer's disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestations of systemic autoimmunity, increased emotional reactivity, enhanced expression of the histone vari...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00745-9

    authors: Kapadia M,Mian MF,Ma D,Hutton CP,Azam A,Narkaj K,Cao C,Brown B,Michalski B,Morgan D,Forsythe P,Zovkic IB,Fahnestock M,Sakic B

    更新日期:2021-01-20 00:00:00

  • Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study.

    abstract:BACKGROUND:Antidepressant use has been associated with an increased risk of falling, but no studies have been conducted on whether antidepressant use is associated with an increased risk of head injuries which often result from falling among older persons. The objective of this study was to investigate the risk of head...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0285-3

    authors: Taipale H,Koponen M,Tanskanen A,Lavikainen P,Sund R,Tiihonen J,Hartikainen S,Tolppanen AM

    更新日期:2017-08-01 00:00:00

  • Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

    abstract::The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-019-0485-0

    authors: Hansson O,Lehmann S,Otto M,Zetterberg H,Lewczuk P

    更新日期:2019-04-22 00:00:00

  • Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.

    abstract:INTRODUCTION:MAPT encodes for tau, the predominant component of neurofibrillary tangles that are neuropathological hallmarks of Alzheimer's disease (AD). Genetic association of MAPT variants with late-onset AD (LOAD) risk has been inconsistent, although insufficient power and incomplete assessment of MAPT haplotypes ma...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt268

    authors: Allen M,Kachadoorian M,Quicksall Z,Zou F,Chai HS,Younkin C,Crook JE,Pankratz VS,Carrasquillo MM,Krishnan S,Nguyen T,Ma L,Malphrus K,Lincoln S,Bisceglio G,Kolbert CP,Jen J,Mukherjee S,Kauwe JK,Crane PK,Haines JL,

    更新日期:2014-07-01 00:00:00

  • Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design.

    abstract::Recent trials of statins produced no benefit for subjects with Alzheimer's disease. These negative studies add to a growing list of negative clinical trials. These data point to a need for reevaluating the pathophysiology of late-onset Alzheimer's disease. Late-onset Alzheimer's disease might result from the cumulativ...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/alzrt101

    authors: Wolozin B

    更新日期:2012-01-16 00:00:00

  • Cognitive and affective theory of mind in dementia with Lewy bodies and Alzheimer's disease.

    abstract:BACKGROUND:Theory of mind (ToM) refers to the ability to attribute mental states, thoughts (cognitive component) or feelings (affective component) to others. This function has been studied in many neurodegenerative diseases; however, to our knowledge, no studies investigating ToM in dementia with Lewy bodies (DLB) have...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0179-9

    authors: Heitz C,Noblet V,Phillipps C,Cretin B,Vogt N,Philippi N,Kemp J,de Petigny X,Bilger M,Demuynck C,Martin-Hunyadi C,Armspach JP,Blanc F

    更新日期:2016-03-16 00:00:00

  • Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey.

    abstract:INTRODUCTION:The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheim...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0525-9

    authors: Bertens D,Vos S,Kehoe P,Wolf H,Nobili F,Mendonça A,van Rossum I,Hort J,Molinuevo JL,Heneka M,Petersen R,Scheltens P,Visser PJ

    更新日期:2019-08-22 00:00:00

  • Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?

    abstract:BACKGROUND:Alzheimer's disease (AD) pathophysiology is mostly (>95%) not inherited in a Mendelian fashion. Such sporadic AD (sAD) forms do not exhibit familial aggregation and are characterized by complex genetic inheritance. Growing evidence indicates that multiple genes contribute to sAD-characteristic endophenotypes...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt165

    authors: Hampel H,Lista S

    更新日期:2013-03-18 00:00:00